Ovid Therapeutics Inc. (OVID) Form 8-K — Jun 3, 2026
Ovid Therapeutics Inc. announced the appointment of Anna Greka, M.D., Ph.D., as a Class III director, effective June 15, 2026. Dr. Greka joins the board upon recommendation of the Nominating and Corporate Governance Committee, increasing the board size to seven members.
Price after filing
1 day: +3.8%7 days: -4.6%30 days: +12.6%
Close on the filing date to close N calendar days later (from $2.39). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.